Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics as adjuvant therapy for reflux esophagitis
ChiCTR2200059624Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Nanchang
- Start
- May 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of Lactobacillus rhamnosus GG in erosive esophagitis (EE) (3 arms), sponsored by The First Hospital of Nanchang. Primary endpoints: Clinical symptoms, Endoscopy and 3 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
Lactobacillus rhamnosus GG
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on ChiCTR2200059624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059624.